{"groups":[{"description":"Patients receive 1000mg/m\\^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 1.4mg/m\\^2 eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nEribulin Mesylate: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"FG000","title":"Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"comment":"Two enrolled patients did not receive any study treatment and were excluded from analysis.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Twenty-six patients were enrolled, but 2 did not receive treatment due to medication compliance related to diabetes and another deemed ineligible after registration but prior to treatment start."}